Evaluating quality of life after chemoradiation in anal cancer patients
Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)
This study looks at how treatment with chemoradiation affects the quality of life for people with anal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich Academic / other |
| Locations | 1 site (Munich, Bavaria) |
| Trial ID | NCT03792854 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the quality of life in patients with anal cancer who have undergone definitive chemoradiation. It will utilize standardized EORTC questionnaires to evaluate longitudinal quality of life, functional outcomes, oncological outcomes, and toxicity. The study will monitor both acute and late toxicities and analyze correlations between physician and patient-reported outcomes. The findings will provide insights into the overall impact of treatment on patients' lives.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically proven anal cancer who are scheduled for definitive chemoradiation therapy.
Not a fit: Patients under 18 years old, those with distant metastases, or those who have received prior systemic therapy for anal cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the quality of life and treatment outcomes for anal cancer patients, leading to improved patient care.
How similar studies have performed: While this study focuses on quality of life in anal cancer patients, similar observational studies have shown success in evaluating treatment outcomes and patient experiences in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histologically proven anal cancer without distant metastases * indication for definitive chemoradiation therapy based on multidisciplinary evaluation * age \>=18 years * written informed consent * ability to answer the standardized questionaires according to the treating physician Exclusion Criteria: * age \< 18 years * prior systemic therapy with regard to anal cancer * distant metastases * second malignancy
Where this trial is running
Munich, Bavaria
- Department of Radiation Oncology, University Hospital, LMU Munich — Munich, Bavaria, Germany (Recruiting)
Study contacts
- Principal investigator: Falk Roeder, MD — Ludwig-Maximilians Universität München
- Study coordinator: Falk Roeder, MD
- Email: falk.roeder@t-online.de
- Phone: +49894400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.